Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprolide acetate depot 3.75 mg in prostate cancer
2005-002880-98Phase 3Completed
- Sponsor
- GP Pharm
- Start
- Oct 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, single-arm trial of leuprolide in prostate cancer (PCa), sponsored by GP Pharm. Primary endpoint: Plasma testosterone suppression below castration levels. Started Oct 2005; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-002880-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002880-98.